IGF2BP1 and lung carcinoma: This study showed that tRF‐16 can decrease IGF2BP1's ability to bind to CPT1A and decrease CPT1A's stability, which can impact lung cancer cells' fatty acid metabolism and promote both in vivo and in vitro growth.